European Journal of Futures Research
April 30, 2022
Claudia Schwarz-Plaschg
36 citations
After decades of criminalization, psychedelics like psilocybin and LSD are being reintegrated into Western science and culture. Based on three years of ethnographic research in the US, this article identifies four socio-psychedelic imaginaries—biomedicalization, decriminalization, legalization, and sacramental—that represent collective visions for legally and responsibly reintegrating these substances. These imaginaries diverge and converge around politics of access, responsibility, naming, assimilation and social change, and epistemic credibility. They co-evolve and amplify each other, functioning as a societal corrective to politically motivated prohibition. The radical imagination expressed in these imaginaries arises from human-psychedelic entanglements.
J Palliat Med
April 13, 2021
Yvan Beaussant, James Tulsky, Benjamin Guérin et al.
34 citations
Researchers from palliative care, psychosocial oncology, spiritual care, oncology, and psychedelic-assisted therapies identified seven key opportunities for advancing research on psychedelic-assisted therapy for people with serious illness. Four opportunities relate to science and design: clarifying which conditions the therapy is indicated for, developing and refining therapeutic protocols, investigating how set and setting affect outcomes, and understanding mechanisms of action. Three opportunities concern institutional and societal drivers: education and certification for therapists, regulations and funding, and diversity and inclusion. Participants also noted epistemological limitations of the medical model for understanding psychedelics' therapeutic value.
J Palliat Med
April 13, 2021
Yvan Beaussant, James Tulsky, Benjamin Guérin et al.
34 citations
Researchers from palliative care, psychosocial oncology, spiritual care, oncology, and psychedelic-assisted therapies identified seven key opportunities for advancing research on psychedelic-assisted therapy for people with serious illness. Four opportunities relate to science and design: clarifying which conditions the therapy is indicated for, developing and refining therapeutic protocols, investigating how set and setting affect outcomes, and understanding mechanisms of action. Three opportunities concern institutional and societal drivers: education and certification for therapists, regulations and funding, and diversity and inclusion. Participants also noted epistemological limitations of the medical model for understanding psychedelics' therapeutic value.